Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta.
Indian J Ophthalmol
;
2012 May; 60(3): 229-231
Article
in English
| IMSEAR
| ID: sea-139480
ABSTRACT
A 12-year-old girl, diagnosed of osteogenesis imperfecta, presented with sudden visual loss in the left eye. Investigations revealed an active choroidal neovascular membrane. She underwent treatment with intravitreal Bevacizumab (1.25 mg/0.05 ml). Follow-up at 1 month revealed the development of lacquer crack running through the macula, underlying the fovea. The patient received two re-treatments at 1-month intervals, following which the choroidal neovascularization (CNV) regressed completely. However, further progression of lacquer cracks was noted. At the last follow-up, 6 months following the last injection, the fundus remained stable and vision was maintained at 20/200. Considering the natural history of the disease and the increased risk of rupture of the Bruch's membrane in such eyes, the possible complication of a lacquer crack developing must be borne in mind, before initiating treatment.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Osteogenesis Imperfecta
/
Female
/
Humans
/
Fluorescein Angiography
/
Child
/
Follow-Up Studies
/
Disease Progression
/
Choroidal Neovascularization
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
/
Risk factors
Language:
English
Journal:
Indian J Ophthalmol
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS